Globeflex Capital L P Grows Stake in ANI Pharmaceuticals, Inc. $ANIP

Globeflex Capital L P raised its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 80.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 55,361 shares of the specialty pharmaceutical company’s stock after purchasing an additional 24,757 shares during the quarter. Globeflex Capital L P owned about 0.25% of ANI Pharmaceuticals worth $4,370,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Hantz Financial Services Inc. raised its position in ANI Pharmaceuticals by 202.6% in the third quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock valued at $32,000 after purchasing an additional 237 shares during the period. Advisors Asset Management Inc. purchased a new position in ANI Pharmaceuticals in the first quarter valued at about $28,000. State of Wyoming purchased a new position in ANI Pharmaceuticals in the second quarter valued at about $50,000. Federated Hermes Inc. purchased a new position in ANI Pharmaceuticals in the third quarter valued at about $93,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in ANI Pharmaceuticals by 30.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,091 shares of the specialty pharmaceutical company’s stock valued at $86,000 after purchasing an additional 253 shares during the period. 76.05% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. Weiss Ratings reissued a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research report on Monday. Zacks Research lowered ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Finally, Wall Street Zen raised ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Five analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, ANI Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $107.33.

Insider Buying and Selling at ANI Pharmaceuticals

In other news, VP Meredith Cook sold 500 shares of ANI Pharmaceuticals stock in a transaction dated Wednesday, May 13th. The stock was sold at an average price of $78.16, for a total transaction of $39,080.00. Following the sale, the vice president directly owned 78,390 shares of the company’s stock, valued at approximately $6,126,962.40. The trade was a 0.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Patrick D. Walsh sold 10,000 shares of ANI Pharmaceuticals stock in a transaction dated Wednesday, May 13th. The stock was sold at an average price of $80.63, for a total value of $806,300.00. Following the completion of the transaction, the director owned 38,432 shares of the company’s stock, valued at $3,098,772.16. This trade represents a 20.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 81,638 shares of company stock valued at $6,348,562. Company insiders own 8.10% of the company’s stock.

ANI Pharmaceuticals Stock Up 5.3%

Shares of NASDAQ ANIP opened at $79.20 on Friday. ANI Pharmaceuticals, Inc. has a 1 year low of $59.61 and a 1 year high of $99.50. The firm has a market cap of $1.80 billion, a price-to-earnings ratio of 20.05 and a beta of 0.44. The company has a debt-to-equity ratio of 1.06, a quick ratio of 2.52 and a current ratio of 3.12. The stock’s 50-day simple moving average is $78.92 and its 200-day simple moving average is $79.38.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.28 by $0.77. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.The business had revenue of $237.46 million for the quarter, compared to analyst estimates of $207.63 million. During the same period in the previous year, the company earned $1.70 earnings per share. The company’s revenue for the quarter was up 20.5% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, equities analysts anticipate that ANI Pharmaceuticals, Inc. will post 7.96 earnings per share for the current fiscal year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.